用于癌症治疗的"按需活动"的细胞因子生物制药
Giulia Rotta1,2, Emanuele Puca3, Samuele Cazzamalli1
1Philochem AG, CH-8112 Otelfingen, Switzerland.
Bioconjugate chemistry
|June 17, 2024
概括
再组合细胞因子和免疫细胞因子在癌症治疗中表现有前途,但面临毒性挑战. 针对"按需活动"免疫细胞因子的策略旨在通过向瘤,同时保护健康组织来提高耐受性和治疗疗效.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 生物技术是生物技术.
背景情况:
- 细胞因子是免疫调节蛋白质,在癌症中具有治疗潜力.
- 再组合细胞因子在癌症治疗中使用,但在低剂量时经常表现出显著的毒性.
- 免疫细胞因子,或抗体-细胞因子融合,旨在更具体地向瘤.
研究的目的:
- 审查开发抗体-细胞因子融合的策略,以提高耐受性和有效性.
- 探索在免疫细胞因子中实现"按需活动"的方法.
- 概述新型免疫细胞因子方法的潜力和局限性.
主要方法:
- 对复合细胞因子和免疫细胞因子的现有文献的综述.
- 分析创建具有受控活性的抗体-细胞因子融合的策略.
- 评估改善免疫细胞因子治疗指数的方法.
主要成果:
- 免疫细胞因子可以通过激活瘤居民白细胞来增强抗瘤免疫力.
- 目前的免疫细胞因子仍然可能由于完整的细胞因子活性引起毒性.
- 目前正在开发几种策略,以在瘤部位实现局部或可诱导的细胞因子活性.
结论:
- 开发具有"按需活动"的免疫细胞因子对于改善癌症治疗至关重要.
- 有针对性的输送和受控的细胞因子激活可能会增加治疗剂量并减少全身毒性.
- 对这些先进的免疫细胞因子策略的进一步研究对更有效,更安全的癌症治疗有显著的前景.
相关概念视频
Tumor Immunotherapy
511
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
511
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Positive Regulator Molecules
5.4K
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
5.4K
The JAK-STAT Signaling Pathway
8.8K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.8K
M-Cdk Drives Transition Into Mitosis
5.6K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.6K


